Full Press Release Details
dupixent dupilumab sbla accepted for fda priority review for the targeted treatment of bullous pemphigoid bp.
REGN
dupixent dupilumab sbla accepted for fda priority review for the targeted treatment of bullous pemphigoid bp
Key Takeaway: dupixent dupilumab sbla accepted for fda priority review for the targeted treatment of bullous pemphigoid bp